Literature DB >> 9429939

Advances in treatment of retinal angiomas.

J D Palmer1, E S Gragoudas.   

Abstract

Retinal angiomas are benign vascular hamartomatous lesions with important systemic and visual implications. Early diagnosis and treatment of retinal angiomas with an appropriate systemic workup for associated systemic diseases can prevent visual loss and morbidity and mortality. Tumors less than 3 mm in diameter usually can be ablated with laser photocoagulation. Cryotherapy should be reserved for eyes in which media opacities prohibit use of the laser or the tumor is located in an area of shallow serous detachment or in the extreme peripheral retina. Macular puckers or tractional macular detachments caused by retinal angiomas can be treated effectively by pars plana vitrectomy combined with photocoagulation or cryotherapy to the retinal angioma. Penetrating diathermy is a useful alternative therapy for large tumors but is fraught with risks of hemorrhage and inadvertent retinal breaks with or without vitreous loss or retinal detachment. We have found proton-beam irradiation to be an efficacious and safe treatment for large retinal angiomas (> 3 mm) and for cases complicated by exudative retinal detachments or for tumors involving the optic nerve. We believe this new, noninvasive therapy is a significant advance in the treatment of complicated retinal angiomas or for those tumors that have failed to respond to conventional measures.

Entities:  

Mesh:

Year:  1997        PMID: 9429939     DOI: 10.1097/00004397-199703740-00014

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN: 0020-8167


  7 in total

1.  Unilateral hemi-central retinal vein obstruction associated with retinal racemose angioma.

Authors:  Chen Yang; Yu Ling Liu; Hong Liang Dou; Xing Rong Lu; Fang Qian; Lin Zhao
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

2.  Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases.

Authors:  Lynn J Poole Perry; Frederick A Jakobiec; Fouad R Zakka; Elias Reichel; Martina C Herwig; Arie Perry; Daniel J Brat; Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2012-12-06       Impact factor: 5.258

Review 3.  [Retinal angiomatosis. Ocular manifestation of von Hippel-Lindau disease].

Authors:  B Junker; D Schmidt; H T Agostini
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations.

Authors:  Emily Ying Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 5.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

6.  Vasoproliferative tumours of the retina.

Authors:  H Heimann; N Bornfeld; O Vij; S E Coupland; N E Bechrakis; U Kellner; M H Foerster
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

Review 7.  Von Hippel-Lindau Disease and the Eye.

Authors:  Saeed Karimi; Amir Arabi; Toktam Shahraki; Sare Safi
Journal:  J Ophthalmic Vis Res       Date:  2020-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.